This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: City of Hope, Imugene Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Monil Shah: Inventor in Oncolytic Virus Research
Introduction
Monil Shah is an inventor associated with Sydney, Australia, and research into cancer immunotherapy. His patent work describes an approach combining oncolytic viruses with immune-cell engagement to target solid tumors.
Latest Patents
Shah is named on 1 patent: “Methods Comprising Oncolytic Viruses Expressing CD19T and Bispecific T Cell Engagers.” The patent describes oncolytic viruses expressing truncated human CD19 (CD19t) and methods for treating solid tumors by administering such a virus, optionally alongside a T-cell engager targeted to CD19.
Career Highlights
Shah has been associated with City of Hope and Imugene Ltd. His patent reflects work at the intersection of virotherapy and immunotherapy, using engineered viruses and T-cell engagers as potential components of cancer treatment.
Collaborations
Shah’s listed coworkers include Saul J. Priceman and Anthony K. Park. Their shared research context includes the development of approaches involving oncolytic viruses and immune-based cancer therapies.
Conclusion
Monil Shah’s patent work focuses on combining engineered oncolytic viruses with targeted T-cell engagement as a potential strategy for treating solid tumors.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile